Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928381 | 0.89 | PTPN1 (0.36) | PKMHSD11B1 | |
| SCHEMBL29464364 | 0.89 | PTPN1 (0.36) | PKMHSD11B1 | |
| SCHEMBL19951312 | 0.87 | PKM (0.35) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL29464517 | 0.87 | PKM (0.35) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL29464301 | 0.86 | PKM (0.40) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL19968765 | 0.86 | PKM (0.40) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL29464325 | 0.83 | SCN1A (0.37) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL19968754 | 0.83 | HSD11B1 (0.38) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL19925090 | 0.83 | SCN1A (0.37) | PKMHSD11B1GAAKDM4ELMNA | |
| SCHEMBL29464324 | 0.83 | HSD11B1 (0.38) | PKMHSD11B1GAAKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | PKM 371/4885HSD11B1 3742/4885GAA 780/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | PKM 371/4885HSD11B1 3742/4885GAA 780/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | PKM 371/4885HSD11B1 3742/4885GAA 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.